{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:47:42Z","timestamp":1785260862187,"version":"3.55.0"},"reference-count":50,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"unspecified","delay-in-days":350,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. Psychiatr."],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0924933824017978_sec1\">\n\t    <jats:title>Background<\/jats:title>\n\t    <jats:p>Substance use may be associated with the onset of psychotic symptoms, necessitating treatment for individuals with comorbid mental health and substance use disorders (MHD\/SUD). COVID-19 significantly impacted individuals with MHD\/SUD, reducing access to appropriate care and treatment. Changes in drug availability and prices during the pandemic may have influenced drug consumption. This study aimed to determine the frequency of substance-induced psychosis (SIP) during COVID-19 among individuals with MHD\/SUD and to explore substance fidelity by following patterns of SIP over time.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933824017978_sec2\" sec-type=\"methods\">\n\t    <jats:title>Method<\/jats:title>\n\t    <jats:p>In this retrospective cohort study, we analyzed data from all individuals with MHD\/SUD registered in 2019\u20132021 in the Norwegian Patient Register. We used graphical approaches, descriptives, and Poisson regression to study occurrence and risk of SIP episodes in the three-year observation period. Sankey diagrams were used to examine trajectories of psychotic episodes induced by various substances.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933824017978_sec3\" sec-type=\"results\">\n\t    <jats:title>Results<\/jats:title>\n\t    <jats:p>Despite a decrease in individuals diagnosed with SIP during COVID-19, SIP episodes increased overall. We observed a decline in cannabis-induced psychosis, but a rise in SIP episodes involving amphetamines and multiple substances. Among individuals with recurrent SIP episodes, the psychosis was more often induced by different substances during COVID-19 (2020: RR, 1.50 [95% CI, 1.34\u20131.67]; 2021: RR, 1.30 [95% CI, 1.16\u20131.46]) than in 2019.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924933824017978_sec4\" sec-type=\"conclusions\">\n\t    <jats:title>Conclusion<\/jats:title>\n\t    <jats:p>During COVID-19, fewer individuals were hospitalized with SIP, but those patients experienced more episodes. There were fewer cannabis-induced psychotic episodes, but more SIP hospitalizations caused by central stimulants and more SIP diagnoses caused by different substances, possibly reflecting changes in drug availability and pricing.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1192\/j.eurpsy.2024.1797","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:30:21Z","timestamp":1734337821000},"source":"Crossref","is-referenced-by-count":4,"title":["Frequency and patterns of substance-induced psychosis in persons with concurrent mental health and substance use disorders during the COVID-19 pandemic: A Norwegian register-based cohort study"],"prefix":"10.1192","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-3949","authenticated-orcid":false,"given":"Marja","family":"Leonhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3144","authenticated-orcid":false,"given":"J\u00f8rgen G.","family":"Bramness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7248-3019","authenticated-orcid":false,"given":"Eline Borger","family":"Rognli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-9208","authenticated-orcid":false,"given":"Lars","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"S0924933824017978_r21","unstructured":"[21] The Independent Coronavirus Commission. Management of the pandemic by the Norwegian authorities - Part 2. In Norge offentlige utredningre - Norway\u2019s public investigations. Oslo: The ministries\u2019 Security and Service Organization Technical Editorial Staff; 2022."},{"key":"S0924933824017978_r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108514"},{"key":"S0924933824017978_r36","unstructured":"[36] United Nations. World Drug Report 2021. Vienna; 2021."},{"key":"S0924933824017978_r12","article-title":"Health improvements needed in persons with mental disorders and substance use disorders","volume":"144","author":"Skeie","year":"2024","journal-title":"Tidsskr Nor Laegeforen"},{"key":"S0924933824017978_r11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0024597"},{"key":"S0924933824017978_r42","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-021-00373-y"},{"key":"S0924933824017978_r49","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-23961-3_7"},{"key":"S0924933824017978_r14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182010830"},{"key":"S0924933824017978_r30","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.101715"},{"key":"S0924933824017978_r39","unstructured":"[39] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2021: trends and developments. Luxemburg: Publications Office of the European Union; 2021."},{"key":"S0924933824017978_r22","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00601-z"},{"key":"S0924933824017978_r10","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1832-6"},{"key":"S0924933824017978_r23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.633551"},{"key":"S0924933824017978_r25","unstructured":"[25] Mustian, J , Bleiberg, J . Cartels are scrambling\u2019: virus snarls global drug trade. AP NEWS; 2020."},{"key":"S0924933824017978_r31","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"S0924933824017978_r6","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719003532"},{"key":"S0924933824017978_r17","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-03812-7"},{"key":"S0924933824017978_r26","unstructured":"[26] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Impact of COVID-19 on drug markets, use, harms and drug services in the community and prisons: results from an EMCDDA trendspotter study. Publications Office of the European Union Luxembourg; 2021."},{"key":"S0924933824017978_r16","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-05497-6"},{"key":"S0924933824017978_r37","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04185-7"},{"key":"S0924933824017978_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114361"},{"key":"S0924933824017978_r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103752"},{"key":"S0924933824017978_r50","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz102"},{"key":"S0924933824017978_r43","unstructured":"[43] TV2. Narcotics draught in Oslo\u2014price has increased 500%; 2020."},{"key":"S0924933824017978_r19","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-023-00564-9"},{"key":"S0924933824017978_r3","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"S0924933824017978_r15","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2022.2051110"},{"key":"S0924933824017978_r8","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30078-0"},{"key":"S0924933824017978_r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2021.106540"},{"key":"S0924933824017978_r44","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17020223"},{"key":"S0924933824017978_r45","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101217"},{"key":"S0924933824017978_r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2017.04.014"},{"key":"S0924933824017978_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104048"},{"key":"S0924933824017978_r1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12280"},{"key":"S0924933824017978_r5","first-page":"1","article-title":"Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016","author":"Rognli","year":"2022","journal-title":"Psychol Med"},{"key":"S0924933824017978_r32","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2022.104"},{"key":"S0924933824017978_r38","unstructured":"[38] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EU Drug market: methamphetamine\u2014in-depth analysis. Luxemburg; 2022."},{"key":"S0924933824017978_r4","volume-title":"The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines","year":"2004"},{"key":"S0924933824017978_r40","unstructured":"[40] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2024: trends and developments. Luxemburg; 2024."},{"key":"S0924933824017978_r7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.046375"},{"key":"S0924933824017978_r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"S0924933824017978_r13","doi-asserted-by":"publisher","DOI":"10.1177\/00368504211019854"},{"key":"S0924933824017978_r24","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2020.1857408"},{"key":"S0924933824017978_r33","doi-asserted-by":"publisher","DOI":"10.1159\/000515102"},{"key":"S0924933824017978_r18","unstructured":"[18] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Trendspotter briefing\/Impact of COVID-19 on drug services and help-seeking in Europe. Lisbon; 2020."},{"key":"S0924933824017978_r28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.648273"},{"key":"S0924933824017978_r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105691"},{"key":"S0924933824017978_r41","unstructured":"[41] KRIPOS. Narcotis and doping statistics 2021. Oslo: Police; 2022."},{"key":"S0924933824017978_r46","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07822"},{"key":"S0924933824017978_r48","doi-asserted-by":"publisher","DOI":"10.1111\/add.16008"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924933824017978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T08:30:26Z","timestamp":1734337826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924933824017978\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S0924933824017978"],"URL":"https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1797","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e82"}}